Compare Live Nation Entertainment, Inc. (LYV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs McKesson Corporation — how do they compare? Live Nation Entertainment, Inc. trades at $178 (market cap $42.09B), while McKesson Corporation trades at $829.95 (market cap $97.35B). The key difference: McKesson Corporation is far larger — about 2.3× Live Nation Entertainment, Inc.'s market cap, and McKesson Corporation pays a 0.39% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | MCK | |
|---|---|---|
Market Cap | $42.09B | $97.35B |
Sector | Industrials | Health |
52-Week High | $186.59 | $995.69 |
52-Week Low | $125.61 | $659.01 |
Enterprise Value | $43.59B | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation (LYV) trades at $180.84, up 0.34% today, with bullish technical signals from moving averages despite recent earnings misses. The company reported $25.2B revenue for 2025 with a slim 0.33% net margin, while valuation metrics show elevated P/E (117.49) and P/B (136.72) ratios. Recent news highlights executive share sales and ongoing legal scrutiny, though analyst consensus remains strongly bullish with an $200.20 price target.
Outlook remains mixed with strong revenue growth potential from concert demand and ticketing margins offset by profitability challenges and legal overhangs. The stock offers upside to analyst targets but faces execution risks amid high valuations and recent earnings volatility.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
